<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838407</url>
  </required_header>
  <id_info>
    <org_study_id>115813</org_study_id>
    <nct_id>NCT02838407</nct_id>
  </id_info>
  <brief_title>Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.</brief_title>
  <official_title>Identification and Characterization of Bacteria in the Lower Airways of Children Aged ≥ 6 Months to &lt; 6 Years With Suspected Lower Respiratory Tract Infections (LRTI) in Spain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify and characterise bacteria present in the lower
      airways of children with suspected chronic LRTIs and for whom bronchoalveolar lavage (BAL) is
      indicated by the clinician.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with H. influenzae, S. pneumoniae, M. catarrhalis and other bacteria in BAL fluid samples of subjects aged ≥ 6 months to &lt; 6 years with suspected chronic LRTIs and an indication for BAL.</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and indication for BAL, number of subjects in load categories for H. influenzae, S. pneumoniae and M. catarrhalis in BAL fluid, as determined by quantitative culture and Polymerase Chain Reaction.</measure>
    <time_frame>Day 0</time_frame>
    <description>In a hospital setting and among subjects aged ≥ 6 months to &lt; 6 years with suspected chronic LRTIs and an indication for BAL, the distribution (with number of non-missing observations, mean, standard deviation, median, minimum and maximum and number of missing observations) of the bacterial load of H. influenzae, S. pneumoniae, M. catarrhalis in the BAL fluid will be described according to the testing method (culture and Polymerase Chain Reaction [PCR].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and an indication for BAL, number of subjects with other bacterial pathogens in the BAL fluid as determined by qualitative culture.</measure>
    <time_frame>Day 0</time_frame>
    <description>The presence (number and percentage) of other bacterial isolates detected in BAL fluid will be presented in frequency tables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and indication for BAL, number of subjects in load categories for H. influenzae, S. pneumoniae and M. catarrhalis in nasopharyngeal swab samples as determined by quantitative culture and PCR.</measure>
    <time_frame>Day 0</time_frame>
    <description>In a hospital setting and among subjects aged ≥ 6 months to &lt; 6 years with suspected chronic LRTIs and an indication for BAL, the distribution (with number of non-missing observations, mean, standard deviation, median, minimum and maximum and number of missing observations) of the bacterial load of H. influenzae, S. pneumoniae, M. catarrhalis in the nasopharyngeal swab samples will be described according to the testing method (culture and PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and an indication for BAL, number of subjects with other bacterial pathogens in nasopharyngeal swab samples as determined by qualitative culture.</measure>
    <time_frame>Day 0</time_frame>
    <description>The presence (number and percentage) of other bacterial isolates detected in the nasopharyngeal swab samples will be presented in frequency tables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and indication for BAL, number of subjects with H. influenzae, S. pneumoniae, M. catarrhalis and other pathogens detected by culture in nasopharyngeal swab samples.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and an indication for BAL, number of subjects with H. influenzae and S. pneumoniae serotypes identified from BAL fluid samples and nasopharyngeal swab samples.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and indication for BAL, number of subjects with H. influenzae, S. pneumoniae and M. catarrhalis minimum inhibitory concentration values identified from BAL fluid and nasopharyngeal swab samples.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and an indication for BAL, descriptive statistics for demographic characteristics,(age, gender, etc).</measure>
    <time_frame>Day 0</time_frame>
    <description>In a hospital setting and among subjects aged ≥ 6 months to &lt; 6 years with suspected chronic LRTIs and an indication for BAL, demographic characteristics (age, gender, weight, height) will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and an indication for BAL, number of subjects with clinical characteristics.</measure>
    <time_frame>Day 0</time_frame>
    <description>In a hospital setting and among subjects aged &gt;=6 months to &lt; 6 years with suspected chronic LRTIs and an indication for BAL, clinical characteristics (including medical history, LRTI symptoms, treatment history, vaccination status, etc.) will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and an indication for BAL, number of subjects with radiological evidence.</measure>
    <time_frame>Day 0</time_frame>
    <description>In a hospital setting and among subjects aged ≥ 6 months to &lt; 6 years with suspected chronic LRTIs and an indication for BAL, radiological evidence will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For enrolled subjects with suspected chronic LRTIs and an indication for BAL, number of subjects with laboratory results.</measure>
    <time_frame>Day 0</time_frame>
    <description>In a hospital setting and among subjects aged ≥ 6 months to &lt; 6 years with suspected chronic LRTIs and an indication for BAL, laboratory results (including white blood cell counts, C-Reactive Protein [CRP] level and erythrocyte sedimentation rate, if available) will be presented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Total group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled subjects who visited the hospital with suspected chronic LRTIs and for whom BAL fluid and/or nasopharyngeal swab samples have been collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BAL fluid sampling</intervention_name>
    <description>Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.</description>
    <arm_group_label>Total group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasopharyngeal swab sampling</intervention_name>
    <description>1 swab, Day 0</description>
    <arm_group_label>Total group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that parent(s)/ legally acceptable
             representatives (LAR[s]) can and will comply with the requirements of the protocol.

          -  A male or female subject aged ≥ 6 months to &lt; 6 years at the time of enrolment.

          -  Subjects meet the case definition of suspected chronic LRTIs where BAL is indicated.

          -  Subject's parent(s)/ LAR(s) agree to the collection of a nasopharyngeal swab from the
             subject.

          -  Written informed consent obtained from the parent(s)/ LAR(s) of the subject.

        Exclusion Criteria:

          -  Known cystic fibrosis, immunosuppression, or other severe immunodeficiencies such as
             agammaglobu-linaemia, T cell deficiency or Human Immunodeficiency Virus/ Acquired
             Immune Deficiency Syndrome, chemotherapy treatment, etc.

          -  Exacerbation of persistent respiratory symptoms (cough, wheezing, difficulty in
             breathing, etc.) in the previous 2 weeks.

          -  Antibiotic treatment in the 2 weeks prior to study entry.

          -  Concurrent participation in another study within 30 days prior to study entry or at
             any time during the study period, in which the subject has been or will be exposed to
             an investigational or a non-investigational product (pharmaceutical product or
             device).

          -  Subjects having previously participated in this study.

          -  Child in care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barakaldo (Vizcaya)</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murcia (El Palmar)</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic lower respiratory tract infection</keyword>
  <keyword>Bonchoalveolar lavage</keyword>
  <keyword>Nasopharyngeal swabs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

